Amgen sees no 'significant delays' from pandemic to novel KRAS cancer drug

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

Amgen sees no 'significant delays' from pandemic to novel KRAS cancer drug
Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.